Sign in
ImmunologybioRxiv
Preprint

Driving potent neutralization of a SARS-CoV-2 Variant of Concern with a heterotypic boost

D. J. Sheward, M. Mandolesi, E. Urgard, C. Kim, L. Hanke, L. Perez Vidakovics, A. Pankow, N. L. Smith, X. Castro Dopico, G. M. McInerney, J. M. Coquet, G. Karlsson Hedestam, B. Murrell

Abstract

The emergence of SARS-CoV-2 Variants of Concern (VOCs) with mutations in key neutralizing antibody epitopes threatens to undermine vaccines developed against the pandemic founder variant (Wu-Hu-1). Widespread vaccine rollout and continued transmission are creating a population that has antibody responses of varying potency to Wu-Hu-1. Against this background, it is critical to assess the outcomes of subsequent immunization with variant antigens. It is not yet known whether heterotypic vaccine boosts would be compromised by original antigenic sin, where pre-existing responses to a prior variant dampen responses to a new one, or whether the primed memory B cell repertoire would bridge the gap between Wu-Hu-1 and VOCs. Here, we show that a single adjuvanted dose of receptor binding domain (RBD) protein from VOC 501Y.V2 (B.1.351) drives an extremely potent neutralizing antibody response capable of cross-neutralizing both Wu-Hu-1 and 501Y.V2 in rhesus macaques previously immunized with Wu-Hu-1 spike protein. Passive immunization with plasma sampled following this boost protected K18-hACE2 mice from lethal challenge with a 501Y.V2 clinical isolate, whereas only partial protection was afforded by plasma sampled after two Wu-Hu-1 spike immunizations.

PDFDOI

02 /Specification & Classification

Click any tag to browse matching papers

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISHuang '21Kim '22Law '21Pavot '21Parham '22Narowski '21
79% semantic matchMicrobiology
B. Huang, L. Dai, H. Wang+4 more·bioRxiv·Feb 1, 2021